Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity

Vaccine

Volumn 20, Issue 19-20, 2002, Pages 2537-2545

  Yao, Qizhi ^a,b   Vuong, Vinh ^a   Li, Min ^a   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Intranasal immunization; Mucosal immune response; SIV VLPs

Indexed keywords

CHOLERA TOXIN; ENVELOPE PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; VIRUS VACCINE; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; HUMORAL IMMUNITY; LYMPH NODE; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SALIVA LEVEL; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; VAGINA DISCHARGE; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MOLECULAR GENETICS; SERODIAGNOSIS; VIRION;

ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMAL; ANTIBODIES, VIRAL; FEMALE; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SIV; SUPPORT, U.S. GOV'T, P.H.S.; VIRAL VACCINES; VIRION; ANIMALS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0037035866     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00160-3     Document Type: Article

References (43)

1. Microbial evasion of IgA functions
2. Functional role of mucosal cytotoxic lymphocytes
3. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239
4. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
5. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis
6. Oral tolerance: Physiological basis and clinical applications
7. Mucosal adjuvants
8. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens
9. Cholera toxin adjuvant greatly promotes antigen priming of T cells
10. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression
11. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro
12. Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-β 1
13. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates
14. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues
15. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
16. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection
17. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses
18. Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells
19. Characterization of group specific antibodies in primates: Studies with SIV envelope in macaques
20. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection
21. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system
22. Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates
23. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs
24. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes
25. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
26. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
27. Human immunodeficiency virus type 1 and mucosal humoral defense
28. Mucosal immunity and tolerance: Relevance to vaccine development
29. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues
30. Rotavirus virus-like particles administered mucosally induce protective immunity
31. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo
32. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
33. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens
34. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
35. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
36. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
37. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope
38. Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the "V3" domain
39. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
40. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion
41. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies
42. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitope of gp120
43. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques